{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":12,"podcast":4,"youtube":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03066778\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03066778","nct_id":"NCT03066778","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03066778. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 PLUS etoposide 100 mg/m\\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an area under the plasma drug concentration-time curve \\[AUC\\] 5 IV on Day 1 OR cisplatin 75 mg/m\\^2 IV on Day 1). Participants who stop pembrolizumab as a result of obtaining a response of stable disease (SD), partial response (PR), complete response (CR) or those who stop after receiving pembrolizumab for 24 months for reasons other than disease progression or intolerability, are eligible for up to an additional 1 year of treatment after progressive disease if they meet the criteria for retreatment.","label":"Pembrolizumab+EP","type":"EXPERIMENTAL"},{"description":"During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m\\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m\\^2 IV on Day 1).","label":"Placebo+EP","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-09-21","type":"ACTUAL"},"conditions":["Small Cell Lung Cancer (SCLC)"],"enrollment":{"count":453,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Normal saline solution","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Etoposide","type":"DRUG"}],"last_update":"2022-10-03","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2019-12-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 30.5 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 30.5 months"}],"references":[{"citation":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gumus M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.","pmid":"32468956","type":"RESULT"}],"start_date":{"date":"2017-05-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)","url":"https://clinicaltrials.gov/study/NCT03066778"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03066778"}